首页> 外文期刊>Advances in Interventional Cardiology: Postepy w Kardiologii Interwencyjnej >Direct transcatheter aortic valve implantation – one-year outcome of a?case control study
【24h】

Direct transcatheter aortic valve implantation – one-year outcome of a?case control study

机译:直接经导管主动脉瓣植入术–病例对照研究的一年结果

获取原文
           

摘要

Introduction : Transaortic valve implantation (TAVI) has a?well-established position in the treatment of high-risk and inoperable patients with severe aortic stenosis (AS). The TAVI protocol requires a?pre-dilatation for native valve preparation. Aim : To assess the safety and feasibility of TAVI without pre-dilatation and to compare it with the procedure with pre-dilatation. Material and methods: Out of 101 TAVI patients, in 10 the procedure was performed without balloon predilatation, and 8 patients were included in the analysis. The procedural, echocardiographic, and clinical outcomes were compared with a?case control matched cohort (1 : 2 ratio). A?12-month follow-up was done in all cases. Results: The procedure was successfully completed in all patients in the study group (SG), but there was one procedural failure in the control group (CG). All patients received a?CoreValve (Medtronic) bioprosthesis. There was a?significant immediate decrease in transvalvular gradients (TG) in both study arms after the procedure (SG: mean TG: from 46.0 ±14.0 mm Hg to 10.0 ±4.8 mm Hg, p 2 and CG: 1.67 ±0.25 cm2, p = 0.75). The periprocedural complication rate was equally distributed in both arms. The 12-month all-cause mortality was 12.5% in both groups. Conclusions : The direct TAVI approach seams to be safe and feasible. The clinical and echocardiographic results are not different from those achieved in patients treated with standard TAVI protocol with pre-dilatation.
机译:简介:经主动脉瓣植入术(TAVI)在高危和不能手术的严重主动脉瓣狭窄(AS)患者的治疗中已确立地位。 TAVI协议要求预膨胀以进行天然瓣膜制备。目的:评估不进行预扩张的TAVI的安全性和可行性,并将其与预扩张的程序进行比较。材料和方法:在101例TAVI患者中,有10例在不进行球囊预扩张的情况下进行了手术,分析中包括8例患者。将手术,超声心动图和临床结果与病例对照匹配队列(1:2比率)进行比较。在所有情况下均进行了12个月的随访。结果:研究组(SG)的所有患者均成功完成了该程序,但对照组(CG)仅有一个程序失败。所有患者均接受了CoreValve(Medtronic)生物假体。手术后,两个研究组的跨瓣梯度(TG)均立即下降(SG:平均TG:从46.0±14.0 mm Hg降至10.0±4.8 mm Hg,p 2 和CG:1.67± 0.25 cm 2 ,p = 0.75)。两组的围手术期并发症发生率均等。两组的12个月全因死亡率均为12.5%。结论:直接TAVI方法接缝是安全可行的。临床和超声心动图检查结果与采用标准TAVI方案并进行预扩张的患者所获得的结果没有区别。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号